Literature DB >> 14506324

Endogenous level of kynurenic acid and activities of kynurenine aminotransferases following transient global ischemia in the gerbil hippocampus.

Elzbieta Luchowska1, Piotr Luchowski, Anna Sarnowska, Marian Wielosz, Waldemar A Turski, Ewa M Urbańska.   

Abstract

The accumulated data indicate that massively released excitatory amino acids play a major role in mediating the acute ischemic neuronal degeneration. Kynurenic acid (KYNA), the endogenous glutamate receptor antagonist, displaying a particularly high affinity for the glycine-site of N-methyl-D-aspartate (NMDA) receptor, was shown to ameliorate ischemic brain damage and its altered metabolism was implicated in the pathogenesis of neurodegeneration during ischemia/anoxia. Thus, we investigated the effect of transient global ischemia in gerbils on the endogenous levels of KYNA and the activity of its biosynthethic enzymes, kynurenine aminotransferases I (KAT I) and II (KAT II) in the hippocampus, 24 and 72 h after the ischemic episode. The level of KYNA in CA1 area was not altered 24 and 72 h following transient global ischemia (39.7 +/- 3.1 vs. 44.8 +/- 4.2, and 46.3 +/- 4.0 vs. 47.8 +/- 3.9 fmol/mg of tissue). Similarly, the activities of KATs in CA1 area were not changed and reached 1.91 +/- 0.11 vs. 1.8 +/- 0.19 and 1.86 +/- 0.1 vs. 1.7 +/- 0.15 (KAT I), and 0.56 +/- 0.2 vs. 0.43 +/- 0.16 and 0.54 +/- 0.08 vs. 0.55 +/- 0.17 (KAT II) pmol KYNA/mg of tissue/h, respectively. The presented data indicate that KYNA production is preserved in CA1 area of gerbil hippocampus during early stages after ischemic insult.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506324

Source DB:  PubMed          Journal:  Pol J Pharmacol        ISSN: 1230-6002


  7 in total

Review 1.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

2.  Modifications on the carboxylic function of kynurenic acid.

Authors:  Ferenc Fülöp; István Szatmári; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-10-14       Impact factor: 3.575

3.  The Janus-face kynurenic acid.

Authors:  Eva Rózsa; Hermina Robotka; László Vécsei; József Toldi
Journal:  J Neural Transm (Vienna)       Date:  2008-04-30       Impact factor: 3.575

Review 4.  The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.

Authors:  María Isabel Cuartero; Juan de la Parra; Alicia García-Culebras; Iván Ballesteros; Ignacio Lizasoain; María Ángeles Moro
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 5.  KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect.

Authors:  Bálint Lőrinczi; István Szatmári
Journal:  Int J Mol Sci       Date:  2021-11-03       Impact factor: 5.923

6.  Synthetic- and DFT modelling studies on regioselective modified Mannich reactions of hydroxy-KYNA derivatives.

Authors:  Bálint Lőrinczi; Antal Csámpai; Ferenc Fülöp; István Szatmári
Journal:  RSC Adv       Date:  2020-12-24       Impact factor: 3.361

7.  Synthesis of Indole-Coupled KYNA Derivatives via C-N Bond Cleavage of Mannich Bases.

Authors:  Bálint Lőrinczi; Péter Simon; István Szatmári
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.